Taspoglutide

Drug Profile

Taspoglutide

Alternative Names: BIM 51077; BM 51077; BN 51077; ITM-077; R1583; RG 1583

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Ipsen
  • Developer Roche; Teijin Pharma
  • Class Amino acids; Antihyperglycaemics; Glucagon-like peptides
  • Mechanism of Action Glucagon-like peptide 1 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Type 2 diabetes mellitus

Most Recent Events

  • 11 Jul 2011 Roche terminates a phase III trial in Type-2 diabetes mellitus (insulin-naive patients) in countries worldwide (NCT01051011)
  • 21 Apr 2011 Suspended - Phase-II for Type-2 diabetes mellitus in Japan (SC)
  • 03 Feb 2011 Taspoglutide is no longer licensed to Roche worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top